4Moving Biotech, a spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD) announces the equity investment of the Arthritis Foundation to support the clinical development of its disease-modifying osteoarthritis drug candidate.
“We are very pleased with the commitment of the Foundation Arthritis. Patients have always been the core of our company”, said Prof. Francis Berenbaum, co-founder and CEO/CMO of 4Moving Biotech, Professor at Sorbonne University and head of the rheumatology department at St-Antoine Hospital (AP-HP) in Paris. “The support of a public foundation such as the Arthritis Foundation is a recognition of the quality of our scientific research to bring innovative treatments to osteoarthritis patients worldwide.”
Osteoarthritis is the most frequent chronic destructive disease of the joints. It is the leading cause of disability in people over the age of 50. More than 300 million people are affected worldwide. Nearly one of two adults will develop knee or hip osteoarthritis in their lifetime. In France, more than 8.4 million people live with this disease.
4Moving Biotech has enrolled its first patient for phase I of LASARE clinical trial study.
“Arthritis Foundation has unveiled its “ambition 2030”, which is focused on patient impact and associated with a scientific strategy of funding excellence. I am pleased to give concrete expression to this desire by diversifying our commitments so that the research continuum between a researcher’s idea, his fundamental research and translation to the clinical phases is assured. 4moving Biotech gives meaning to this new 2030 ambition.” said Lionel Comole, directeur général de la fondation Arthritis
For more information : PR-EN-20221108-FArthritisX4MB